HK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform

Stock News11-21

MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million.

The company announced it recently signed a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology to establish a strategic partnership focused on building an RNA-centric platform for preventive and precision medicine. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.

According to the announcement, the partnership aims to leverage the complementary strengths of both companies to create synergies. MIRXES-B will contribute its advanced RNA diagnostic technology, proprietary Asia-centric disease RNA database, and ASEAN manufacturing and regulatory capabilities—including the region's first Industry 4.0 nucleic acid testing and reagent production base—along with local distribution channels. Walvax will provide its proprietary mRNA vaccine technology, robust clinical pipeline, and top-tier vaccine and therapeutic production infrastructure. Together, the collaboration seeks to establish an integrated R&D and commercial deployment platform for preventive and precision medicine.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105010595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 13:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105010595","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform","media":"Stock News","content":"<p>MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million.</p>\n<p>The company announced it recently signed a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology to establish a strategic partnership focused on building an RNA-centric platform for preventive and precision medicine. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.</p>\n<p>According to the announcement, the partnership aims to leverage the complementary strengths of both companies to create synergies. MIRXES-B will contribute its advanced RNA diagnostic technology, proprietary Asia-centric disease RNA database, and ASEAN manufacturing and regulatory capabilities—including the region's first Industry 4.0 nucleic acid testing and reagent production base—along with local distribution channels. Walvax will provide its proprietary mRNA vaccine technology, robust clinical pipeline, and top-tier vaccine and therapeutic production infrastructure. Together, the collaboration seeks to establish an integrated R&D and commercial deployment platform for preventive and precision medicine.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-21 13:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million.</p>\n<p>The company announced it recently signed a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology to establish a strategic partnership focused on building an RNA-centric platform for preventive and precision medicine. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.</p>\n<p>According to the announcement, the partnership aims to leverage the complementary strengths of both companies to create synergies. MIRXES-B will contribute its advanced RNA diagnostic technology, proprietary Asia-centric disease RNA database, and ASEAN manufacturing and regulatory capabilities—including the region's first Industry 4.0 nucleic acid testing and reagent production base—along with local distribution channels. Walvax will provide its proprietary mRNA vaccine technology, robust clinical pipeline, and top-tier vaccine and therapeutic production infrastructure. Together, the collaboration seeks to establish an integrated R&D and commercial deployment platform for preventive and precision medicine.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNA","symbol_name":"Avidity Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1105010595","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105010595","pubTimestamp":1763704100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million. The company announced it recently signed a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300142":"沃森生物","RNA":"Avidity Biosciences, Inc.","BK4585":"ETF&股票定投概念","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK0070":"员工持股","BK1161":"生物科技","BK4139":"生物科技","BK0077":"质押式回购","BK0239":"医药制造","BK4505":"高瓴资本持仓","BK4588":"碎股","BK0046":"生物疫苗","02629":"MIRXES-B"},"translate_title":"港股走势|MIRXES-B(02629)午后涨超5%与Walvax合作打造以RNA为中心的精准医疗平台","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300142":1,"RNA":1,"02629":1},"content_text":"MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million.\nThe company announced it recently signed a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology to establish a strategic partnership focused on building an RNA-centric platform for preventive and precision medicine. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.\nAccording to the announcement, the partnership aims to leverage the complementary strengths of both companies to create synergies. MIRXES-B will contribute its advanced RNA diagnostic technology, proprietary Asia-centric disease RNA database, and ASEAN manufacturing and regulatory capabilities—including the region's first Industry 4.0 nucleic acid testing and reagent production base—along with local distribution channels. Walvax will provide its proprietary mRNA vaccine technology, robust clinical pipeline, and top-tier vaccine and therapeutic production infrastructure. Together, the collaboration seeks to establish an integrated R&D and commercial deployment platform for preventive and precision medicine.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105010595","isCrawlerRequest":true}